Ozempic and Wegovy are drugs that have been proven effective in reducing weight in obese people. In addition, they are also used to treat type 2 diabetes, drug addiction, and alcohol addiction. Both Ozempic and Wegovy use the active ingredient glucagon-like peptide 1 (GLP-1) and now researchers have found a new active ingredient that is more effective.
In clinical trials that are still underway, retatrutide was found to be able to reduce an average of 22.1% of the body weight of its users within 48 weeks. This is better than semaglutide which reduced an average of 13.9% of the body weight of its users within 68 weeks.
Retatrutide was developed by Eli Lilly and Company and is currently in phase 2 clinical trials. Like semaglutide, retatrutide reduces hunger and prevents overeating which helps to lose weight. Clinical trials will continue this year and it will take several more years before it can receive FDA approval and be marketed.